What question did this study set out to answer?

This piece critiques the current use of opioid abatement funds and suggests improvements for their impact.

January 25, 2026

JAMA Viewpoint argues for better use of opioid funds

Puntos clave

This piece critiques the current use of opioid abatement funds and suggests improvements for their impact.
Comparative analysis with the 1998 Master Settlement Agreement for tobacco.
Examination of state authority in distribution of opioid abatement funds.
Assessment of unmet needs for medication-assisted treatment in various states.
States have used opioid funds ineffectively, similar to past tobacco agreements.
Many states still face significant unmet needs for medication-assisted treatment.
Current delegation of authority to states has not adequately addressed the opioid crisis.

Resumen

The reality of opioid abatement funds is that they are “legally porous, ” lawyers write in the January 15 issue of the Journal of the American Medical Association. They began by comparing the funds to the 1998 Master Settlement Agreement (MSA) for tobacco, which gave 9 billion to states for helping fight smoking, and instead wound up in state general funds. The opioid abatement funds also delegate authority to the states. This they write in “The Lifesaving Potential of Opioid Abatement Funds, ” has not worked as well as it could have, because many states still have an “unmet need for medication‐assisted treatment. ” The corresponding author is Christopher Robertson, JD, Ph. D. , of Boston University School of Law.

Me gusta

Guardar

Cite This Study

Alison Knopf (Fri,) studied this question.

synapsesocial.com/papers/6975b2eafeba4585c2d6e65d https://doi.org/https://doi.org/10.1002/adaw.34790

Me gusta

Guardar